gutflix
GI learning, personalised

Summary

EFFICACY OF USTEKINUMAB IN THE TREATMENT OF POST-OPERATIVE RECURRENCE IN A REAL LIFE COHORT OF PATIENTS WITH CROHN'S DISEASE

Franco Scaldaferri

UEG Week Vienna 2024 | Poster

IBD

October 13, 2024

A single-centre retrospective study of 27 Crohn's disease patients found that ustekinumab as second-line therapy for post-operative recurrence after ileocolonic resection achieved 51% endoscopic or radiological remission and 74% treatment persistence at approximately two years.

KEY POINTS

- All 27 patients had prior exposure to one or more biologic drugs and received ustekinumab for either disease recurrence or intolerance to previous therapy at a mean of 21 months post-surgery
- In 19 patients started on ustekinumab for endoscopic or radiological recurrence, 68% achieved endoscopic or radiologic success and 47.3% achieved remission at mean follow-up of 14.4 months
- In 10 patients started on ustekinumab for intolerance to previous therapy without advanced recurrence, 90% had improvement or stability and 50% achieved remission at mean follow-up of 15.5 months
- Overall treatment persistence at approximately two years was 74% with 51% of the entire cohort achieving radiological or endoscopic remission
- This real-world data may inform clinicians managing post-operative Crohn's disease recurrence in patients previously exposed to biologics

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/b5bfcd1e-9112-11ef-bd8a-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.